



A Primer on Prevention, Recognition and Management of Aortic PVL

Monday, October 27th 2025; 4:50 PM - 4:58 PM

Hasan Jilaihawi, MD

Interventional Cardiologist

Director, Multimodality Imaging Corelab

Professor of Cardiology, Smidt Heart Institute


Cedars-Sinai Medical Center,

Los Angeles, CA



TCT[®]

TRANSCATHETER
CARDIOVASCULAR
THERAPEUTICS[®]



Disclosure of Relevant Financial Relationships

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

Nature of Financial Relationship

Grant/Research Support

Consultant Fees/Honoraria

Individual Stock(s)/Stock Options

Scientific Advisory Board

Ineligible Company


Pi-Cardia

Edwards Lifesciences, Medtronic


DASI simulations

DASI simulations, Pi-Cardia

A Primer on Prevention, Recognition and Management of Aortic PVL



Prevention of Aortic PVL




First, a History lesson!


It is the year 2010.....



*Instagram is launched
Facebook surpasses 500m Users*



*Apple releases the
first iPad*



*Justin Bieber explodes to fame
with "Bieber Fever"*



.....and aortic paravalvular leak (PVL) is a **major** and relatively **common** predictor of mortality after TAVR

Study	No. of patients	Significant PV AR, n (%)	Follow-up	HR (95% CI) (multivariable)
Sinning et al	146	22 (15.0)	Up to 1 year	2.4 (1.0–5.4)
Tamburino et al	663	139 (21.0)	Median 18 months	3.79 (1.57-9.10)
Moat et al	877	115/849 (13.6)	> 11 months	1.66 (1.10–2.51)
Gilard et al	3195	316/1915 (16.5)	Median 114 days	2.49 (1.91-3.25)
Abdel-Wahab	690	119 (17.2)	In-hospital	2.43 (1.22-4.85)
Vasa-Nicotera et al	122	20 (16.3)	1-year	4.19 (2.05-8.59)


AND 3D measurements are not used for TAVR in the PARTNER trial!

26 mm Edwards SAPIEN

Severe, dynamic **fatal PVL** with a rocking valve




Cross-sectional CT is a better measure of annular size than 2D TEE



Smallest 2D TEE measurement used for annular sizing: **21.6 mm**
Retrospective measurement of annular area: **797mm²**

Gross undersizing resulted in severe AR and a rocking valve


Cedars-Sinai data: Cross-sectional CT vs 2D TEE



*Cross-sectional CT
measures have
greater
discriminatory
value for PVL than
largest 2D TEE
measurement*

Evidence for 3D TEE?




3D TEE (Qlab) vs 2D TEE





*Cross-sectional **3D TEE** measures have greater discriminatory value for PVL than largest **2D TEE** measurement*

Not only **3D sizing** but also **device iterations** mitigate PVL

Heavily calcified AS with LVOT calcium





29 S3 in heavily calcified AS with LVOT calcium



Sealing skirt mitigates PVL with severe LVOT calcium Now improved further with S3UR



Nodule of calcium prevents full expansion
BUT Zero PVL=no malapposition








Several other platforms also incorporate the benefit of the sealing skirt


Bicuspid Mega-annulus

75 yo male

Non-ischemic cardiomyopathy; ICD; LFLG AS
EF 27%; DI 0.2; AVA 0.5; Mean PG 14 mmHg



Type 1 LR
Non-calcified
raphe;
AoMAX 44 mm



What are the concerns?

- **Embolization / Migration**
- **Paravalvular leak**

DASI Simulation: ROM (Reduced Order Modeling)


Min(mm)/Max(mm)	BE 29 Nominal	+3cc	+5cc
Inflow	26.8/27.4	27.7/28.1	28.8/28.9
Waist	24.8/25.2	27.0/27.1	28.5/28.9
Outflow	27.4/27.8	28.3/28.5	29.2/29.4




BE 29 Nominal



BE 29 +3cc




BE 29 +5cc



**Waist at nominal
deployment
implies device stability**

Simulation: 29 S3 Root Rupture Risk

Left-Right Cusp
Non-Coronary Cusp



BE 29 Nominal

BE 29 +3cc


BE 29 +5cc

Stretch ≥ 1.6
may = \uparrow root injury

Stretch Magnitude	Stretch Magnitude	Stretch Magnitude
Max stretch of 1.2	Max stretch of 1.4	Max stretch of 1.5


Balloon-Expandable 29 Nominal PVL Risk

■ Left-Right Cusp
■ Non-Coronary Cusp




BE 29 Nominal

	BE 29 Nominal
Gap distance	1.0mm; 1.9mm



BE 29 +3cc

	BE 29 +3cc
Gap distance	0.9mm; 1.7mm



BE 29 +5cc


	BE 29 +5cc
Gap distance	0.7mm; 1.4mm

Gaps ≥ 2 mm
may = \uparrow PVL (S3U)


Gaps < 2 mm
Implies no significant PVL

*Threshold is yet to be determined. Please use clinical judgement.

Bicuspid Mega-annulus




**29 S3U
 Deployed @
 Nominal with
 post-dil x1**





**No PVL
 Mean AV
 gradient 4
 mmHg
 EF ↑ to 34%**

Recognition of Aortic PVL





Know which anatomies to have a high expectation for PVL!

Risk phenotype-
73-year-old male with Type 1 L-R fusion and calcified raphe




CT risk phenotype: High
Plan: 29 mm S3 – Double tap




- **PROCEDURE**
- Cerebral protection using Sentinel device
- Transcatheter Aortic Valve Implantation using 29 mm Sapien 3 Ultra Resilia


#MAXIMALIST!



Pre-dilatation with 22mm Z MED II




Initial deployment with -4 cc




Post dilatation with -2 cc

Final result





Intra-procedure TEE






Discharge TTE

Circular deployment – good hemodynamics


Elucidated definitively on TEE




Transcatheter **hemodynamics** can help evaluate *prognostically significant* aortic **PVL**




Transcatheter **hemodynamics** can help evaluate *prognostically significant* aortic **PVL**



Management of Aortic PVL





Management of Aortic PVL – decision making





88-year-old male with Type 1 L-R fusion


CT risk phenotype: High




SOV	Area:	1568	Peri:	142
LVOT	Area:	694.3	Peri:	95.4
Coronary Height	RCA:	14.8	LCA:	16.4




- **PROCEDURE**
- Cerebral protection using Sentinel device
- Transcatheter Aortic Valve Implantation using 29 mm Sapien 3



Pre-dilatation with 20mm Z MED II








Initial deployment with
nominal volume





Post-dilatation with
nominal volume


Persistent PVL due to calcium




**12mm
AVP II
Plug**




***Patient presents to CSMC with BVD (PVL+AS) in 2024
(26 S3 outside institution in 2022)***



Significant paravalvular leak




Restricted bioprosthetic leaflet motion




Transesophageal Echocardiogram

CT shows in vitro sizing for 26 S3 but with **large LVOT**



Outflow: 26.5 mm




Mild: 25.6 mm



Inflow: 26.5 mm




Ao Max: 42.7 mm



Larger LVOT

LVOT: A619



Commissurally aligned; Calcified Leaflets; Minimal waist


Pre-index TAVR CT, prior to index TAVR in 2022

Type 1 LR bicuspid non-calcified raphe



Annulus: 576 mm²





SOV: 38.8 x 39.9 x 38.4 mm




STJ 38.6 x 39.1 mm




LVOT: 566 mm²




Redo TAV: 29 S3UR



***Cerebral Embolic
Protection using
Sentinel***




***Deployment of 29mm
Sapien 3 Ultra Resilia at
nominal volume***






***Post-dilatation with the
Commander balloon at
nominal volume***

Final Result



Discharge



A Primer on Prevention, Recognition and Management of Aortic PVL

- All 3 are heavily dependent on imaging:
- Prevention:
 - Size optimally using 3D imaging, consider simulation
 - Optimize procedurally- predil/postdil
- Recognition:
 - Underestimated by TTE, take clinical cues to have low threshold for TEE
 - Hemodynamics can prognosticate
- Management:
 - Understand the mechanism to best guide safe and effective management